A patient suffering from a rare disease needs an average of five visits with different doctors to obtain a diagnosis, which is often not definitive. Many more steps are needed to define an effective therapy.

This is why it is very important for the the right information to reach the people who need it, at the right time. This is one of the objectives of the Rizzoli Orthopaedic Institute and its potentiated Structure for Rare Skeletal Diseases.

The diagnostic and therapeutic future of sarcomas, extremely aggressive tumors of mesenchymal origin with at least one hundred recognized subtypes, is based on genetics and epigenetics.